INTRODUCTION
Polymorphisms of the gene for cytochrome P450 2D6 (CYP2D6) influence the rate of elimination of CYP2D6 substrates, which represent approximately 20% of commonly prescribed therapeutic drugs. CYP2D6 substrates include antipsychotic drugs (haloperidol and risperidone), antiarrhythmic agents (flecainide and perphenazine), tricyclic antidepressants (imipramine and amitriptyline), β-blockers (metoprolol and carvedilol), and opioids (codeine and tramadol) (Zanger et al., 2004; Ingelman-Sundberg, 2005) . The CYP2D6 gene locus is highly polymorphic, and various point mutations, nucleotide deletions or insertions, gene rearrangements, and multiplication/deletion of the entire CYP2D6 gene, resulting in more than 106 different alleles (http://www.cypalleles.ki.se/cyp2d6.htm), have been reported. These genetic polymorphisms have been implicated in the extreme variability of CYP2D6 activity, whereby subjects can be categorized into ultra-rapid, extensive, intermediate, and poor metabolizers (PMs) based on CYP2D6 genotype (Sachse et al., 1997; Griese et al., 1998; Raimundo et al., 2000) . These phenotypes are distributed unequally in major populations (Dahl et al., 1995a; Bertilsson et al., 2002) . Ethnic differences in the CYP2D6 genotype This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 13, 2009 as DOI: 10.1124 at ASPET Journals on October 14, 2017 dmd.aspetjournals.org Downloaded from frequencies have been observed in a number of populations following the discovery of different debrisoquine phenotypes (Mahgoub et al., 1977; Ingelman-Sundberg, 1999) , and most of the phenotypic variants have been attributed to genetic polymorphisms of CYP2D6 (Zanger et al., 2004; Eichelbaum et al., 2006) . Phenotypic studies have revealed that approximately 5-10% of Caucasians are PMs (Marez et al., 1997; Gaedigk et al., 1999; Bradford, 2002) . However, the frequency of PMs is less than 1% in Asian populations and 0-8% in the African American population (Lou et al., 1987; Lennard et al., 1992; Droll et al., 1998; Bertilsson et al., 2002) . The PM phenotype is mainly attributed to the CYP2D6*3, *4, *5, and *6 alleles, which predict 93-98% of PMs in Whites; these variant alleles have also been found in an African population, albeit at lower frequency (Droll et al., 1998; Xie et al., 2001 ). In contrast, certain nonfunctional allelic variants (CYP2D6*3, *4, and *6) have not been observed in Asians (Heim and Meyer, 1992; Garcia-Barcelo et al., 2000; Kubota et al., 2000) . The CYP2D6*10 allele, the most common allele in Asians at frequencies of up to ~60%, is a reduced function allele and contributes to intermediate metabolism in a large number of Asian subjects (Kubota et al., 2000; Bertilsson et al., 2002) . CYP2D6*18 and *44 have This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 13, 2009 as DOI: 10.1124 at ASPET Journals on October 14, 2017 dmd.aspetjournals.org Downloaded from exclusively been found in Japanese (Chida et al., 1999a; Yamazaki et al., 2003) . Wang et al. (Wang et al., 1999) have reported an Asian-specific PM allele (CYP2D6*14), which has not been detected in Caucasians. CYP2D6*17 has been well described as the most frequent reduced activity allele in African and African Americans (Masimirembwa et al., 1996; Wan et al., 2001; Bradford, 2002) .
There has been a lack of comprehensive reports on updated information regarding the influence of CYP2D6 genotypes on the metabolic activity of CYP2D6 in Korean subjects. Since different ethnic groups exhibit different genetic polymorphisms of CYP2D6, the determination of genotype frequencies and identification of new alleles in a large population of Korean subjects would be helpful in ensuring safe drug therapy. Correlation studies between CYP2D6 genotypes and metabolic activities have been reported in racially different ethnic groups, however, no studies have been carried out in Koreans using dextromethorphan (DM) which is a prototype substrate for CYP2D6. Therefore, this study was undertaken to obtain comparative information on the metabolic index between Korean and other ethnic groups and this would be useful criteria for phenotype/genotype correlation in the volunteers for genotyping analysis. No participants from the previous study (Lee et al., 2006) were included in this study. Genomic DNA was isolated from blood and liver tissue samples using the QIAamp Blood kit (Qiagen, Chatsworth, CA, USA) and stored at -20°C until use. From the 758 genomic DNA samples, 51 subjects were randomly selected for complete DNA sequencing analysis. All subjects recruited in this study were genotyped for CYP2D6 *2, *3, *4, *5, *10, *14, *18, *21, *41, *49, *52, and one novel variant (3877G>A, CYP2D6*60) . Variants exclusively found in Asian populations with clinical consequences were selected for genotyping. However, rare variants in Asia and the variants undetected both in the present study and the previous sequencing report ( Lee et al., 2006) in Koreans were excluded from the screening. The presence of a 100T>C change was collectively described as CYP2D6*10 in the present study. Therefore, the known alleles CYP2D6*10A/B, *36x2, *36 + *10 tandem were not discriminated in the current genotyping method. Detection of CYP2D6*5 (Gaedigk et al., 1999) and detailed methods and primers used have been described previously (Table 1) (Yokoi et al., 1996; Chida et al., 1999b; Chou et al., 2003; Soyama et al., 2004; Lee et al., 2006) .
The presence of gene duplication and the allele carrying the duplication were This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 13, 2009 as DOI: 10.1124 at ASPET Journals on October 14, 2017 dmd.aspetjournals.org Downloaded from determined according to published methods (Lovlie et al., 1996; Sachse et al., 1997; Soyama et al., 2004) . For direct DNA sequencing analysis, the CYP2D6 gene was amplified by Long and Accurate-PCR (LA-PCR) (TaKaRa LA-PCR kit; TaKaRa Shuzo, Shiga, Japan) using the previous reported primers (Lovlie et al., 1996; Gaedigk et al., 1999) . The 6.6-kb LA-PCR product contained all nine exons, the intron/exon boundaries, the 5′-UTR, and 3'-UTR of the CYP2D6 gene. The genomic DNA (200 ng) was dissolved in LA-PCR buffer that contained 3.0 mM MgCl 2 , 0.2 μ M primers, 400 mΜ dNTPs, and 2.5 U of LA-Taq polymerase. After an initial denaturation step at 94°C for 1 min, 30 cycles of 10 s at 98°C, 30 s at 64°C, and 7 min at 72°C were carried out, and the reaction was terminated after a final elongation step at 72°C for 10 min.
The entire PCR product was directly sequenced using the Applied Biosystems Model 377A DNA Sequencer (Table 1) .
On-line bioinformatics tools Phenotyping. The in vivo phenotype study was carried out on 202 subjects (mean age ± SD, 25 ± 3.6), who agreed to follow the experimental schedule.
They were admitted to overnight housing at the Clinical Trial Center of Busan Paik Hospital and were prohibited from taking alcohol or any medicine including food supplements for 1 week before and throughout the trial period.
After emptying the bladder, blank urine was collected and the subjects took a single oral dose of 30 mg DM (Romilar; Roche Korea Co., Ltd, Ansung, Korea).
Food was not allowed 4 h before and after dosing. All the urine produced within 8 h after the administration of DM was collected. The urine volume was measured and aliquots were stored at -20°C until assayed. The DM and dextrophan (DX) levels in the urine were determined by the reverse-phase HPLC with fluorescence detection, as described previously (Ryu et al., 2007) .
The inter-assay precision values for all samples were less than 9.3%. The mean values of urinary metabolic ratio (MR) were used as an index to reflect CYP2D6 activity.
Western blotting. Human liver microsomes were prepared from the randomly chosen liver tissues whose CYP2D6 genotypes were determined as described performed using SAS software (version 9.1.3, SAS Institute, NC, USA). The correlation coefficients between the formation rates of DX and CYP2D6 protein content in the different human liver microsomes (N=49) were calculated by parametric regression analysis using SAS software. A P value less than 0.05 was considered to be statistically significant.
Results
Thirty-eight variant alleles were detected in the direct DNA sequencing analysis of the CYP2D6 gene in 51 Koreans. The frequency of CYP2D6 genetic variants is summarized in Table 2 . Eight SNPs were found within exons, including two new SNPs that cause an amino acid change (E418K) and introduce a stop codon (S183Stop), respectively. The alleles carrying these SNPs were designated as CYP2D6*52 and CYP2D6*60, respectively, by the P450 Nomenclature Committee (http://www.cypalleles.ki.se/cyp2d6.htm). Nine
SNPs in the 5′-UTR (sequenced up to -1800 nucleotides), nineteen SNPs in introns, and two SNPs in the 3′-UTR (500 nucleotides after the stop codon)
were identified. None of these SNPs appear to be involved in alternative splicing or be situated in transcription factor binding sites. All of the 51
This article has not been copyedited and formatted. The final version may differ from this version. individuals containing a 100C>T change were found as CYP2D6*10B in the sequencing analysis as reported in the other independent sequencing study (Lee et al., 2006) . However, the other 707 subjects were only genotyped for the presence of a 100C>T and collectively described as CYP2D6*10. The frequency of CYP2D6*10 in the present study represents the combined calculation from the 51 sequenced and the 707 genotyped subjects. Combined allele frequencies from the 51 sequenced and the 707 genotyped subjects are presented in Table 3 . The most frequent variant allele in the present study (n=758) was CYP2D6*10 (45.6%), followed by CYP2D6*2 (9.9%), *5 (5.6%), *41 (2.2%), *49 (1.4%), *2XN (1%), and the remaining rare alleles (< 1% frequency). CYP2D6*18, *49, and *60 were identified as rare variants in the present study. However these SNPs were not detected in a previous report (Lee et al., 2006) . The observed CYP2D6 allele frequencies were similar to those reported for other Asian populations, with the exception of CYP2D6*49, which was found at a frequency of 0.5% in a Japanese population (Soyama et al., 2004) . The 37 different genotypes are listed, together with their respective frequencies in Table 4 . CYP2D6*1/*10 was the most frequent genotype (26.8%), followed by CYP2D6*10/*10, *1/*1, *2/*10, and *1/*2, which were This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The present study is the first to evaluate the distribution of CYP2D6 variants and their effects on DM metabolism in a large Korean population. CYP2D6*10 was found to be the most frequent allele at 45.6%. The CYP2D6*10 allele has been observed at frequencies of 33-50% in Japanese (Dahl et al., 1995b; Sistonen et al., 2007) and 58.4% in Chinese (Cai et al., 2000) , which suggests that the frequency of this allele is significantly higher in Asian populations than in Caucasian and African populations (Yokoi et al., 1996; Gaedigk et al., 1999) .
We also found that among the non-functional alleles of CYP2D6, the CYP2D6*5 allele was the most frequent at 5.6%, followed by CYP2D6*14, *21, and *18 at frequencies of 0.33%, 0.33%, and 0.26%, respectively.
Genotype-phenotype relationships have been explored using CYP2D6 probe drugs, and observed discordances have led to the discovery of several variants in Asians, such as CYP2D6 *14, *18, *21, *39, and *44 (Yokoi et al., 1996; Chida et al., 1999b; Wang et al., 1999; Shimada et al., 2001; Yamazaki et al., 2003) . Even though no phenotyping data are available for the in subjects of respective genotypes ( Figs. 1 and 2) . One of four microsomes carrying CYP2D6*1/*2 exhibited the lowest amount of protein, but the other three showed relatively high expression profile (Fig.2 A) . The correlation between the protein content and the DM activity was significant, as shown in the inset of Fig. 2A This article has not been copyedited and formatted. The final version may differ from this version. (Lovlie et al., 1996) .
c Reverse primer for the amplification of CYP2D6 gene is described previously (Gaedigk et al., 1999) . 
